Table 2.
Summary of anti-HBs responses at Month 7 (1 month Postdose 3).
| mpHBV SC | Heptavax®-II SC | mpHBV IM | Estimated Difference | |
|---|---|---|---|---|
| (N = 249) | (N = 236) | (N = 79) | (mpHBV | |
| Observed Response | Observed Response | Observed Response | SC−Heptavax®-II SC) | |
| (95% CI) | (95% CI) | (95% CI) | (95% CI) | |
| SPR | 91.6% (228/249) | 82.6% (195/236) | 98.7% (78/79) | 8.9 (3.0,15.1) |
| (87.4%, 94.7%) | (77.2%, 87.2%) | (93.1%, 100.0%) | ||
| GMT | 231.4 | 91.2 | 1064 | |
| (179.8, 297.9) | (69.9, 119.0) | (667.6, 1695) |
SC: subcutaneous injection; IM: intramuscular injection; N: number of participants met per-protocol set; CI: confidence interval; GMT; geometric mean titer in mIU/mL; The SPR is defined as the percentage of participants with anti-HBs≥10 mIU/mL at Month 7.